Related Experiment Videos
Clopidogrel in the management of ischemic heart disease
Erdal Cavusoglu1, Judy Cheng, Rajat Bhatt
1Department of Medicine, Bronx VA Medical Center, Bronx, NY 10468, USA. ECavusoglu@aol.com
Insights
Antiplatelet agents like aspirin and clopidogrel are crucial for treating ischemic heart disease (IHD). Combination therapy shows promise but requires further study to balance benefits against bleeding risks.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ischemic heart disease (IHD) encompasses a spectrum from stable angina to myocardial infarction.
- Platelet aggregation and thrombus formation following atherosclerotic plaque disruption are key to acute coronary syndromes.
Purpose of the Study:
- To review the role of antiplatelet agents in managing IHD.
- To evaluate the efficacy and safety of clopidogrel, particularly in combination with aspirin.
Main Methods:
- Literature review of antiplatelet therapies for IHD.
- Analysis of studies investigating aspirin and clopidogrel in various IHD syndromes.
Main Results:
- Aspirin is the traditional mainstay for IHD treatment.
- Clopidogrel, alone or with aspirin, improves outcomes in IHD patients.
- Combination therapy increases bleeding risk, necessitating further research.
Conclusions:
- Antiplatelet therapy is central to IHD management.
- Optimizing the risk-benefit ratio of combination aspirin and clopidogrel therapy is essential.
Abstract:
Ischemic heart disease (IHD) represents a pathophysiologic continuum consisting of stable angina, unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction. Patients who develop a change in their usual stable pattern of ischemia are classified as having an acute coronary syndrome, which includes patients with unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction. Such progression from a stable to an unstable state is believed to result from disruption of an atherosclerotic plaque with subsequent platelet aggregation and thrombus formation. This, in turn, leads to the clinical manifestations of unstable angina, MI or death. Because platelets play a central role in the thrombotic complications of atherosclerosis, antiplatelet agents have been the cornerstone of the therapy for IHD. Aspirin has been the traditional antiplatelet agent, and remains the mainstay of treatment for all forms of IHD. However, aspirin is a weak antiplatelet agent and is often poorly tolerated by many patients. Clopidogrel is a new antiplatelet agent of the thienopyridine class. Clopidogrel, when used alone, and especially in combination with aspirin, has been shown to improve outcomes in patients with IHD across a variety of syndromes. However, combination therapy with aspirin and clopidogrel has been associated with an increased risk of bleeding. Therefore, despite improved outcomes, further studies are required to determine the optimal duration and dosage regimen of such combination therapy to maximize its risk-benefit ratio.